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Purpose. There is evidence in the literature of increased maternal radiosensitivity during pregnancy. Materials and Methods.
We tested this hypothesis using information from the atomic-bomb survivor cohort, that is, the Adult Health Study database
at the Radiation Eﬀects Research Foundation, which contains data from a cohort of women who were pregnant at the time
of the bombings of Hiroshima and Nagasaki. Previous evaluation has demonstrated long-term radiation dose-response eﬀects.
Results/Conclusions. Data on approximately 250 women were available to assess dose-response rates for serum cholesterol, white
bloodcellcount,erythrocytesedimentationrate,andserumhemoglobin, andonapproximately85women forstablechromosome
aberrations, glycophorin A locus mutations, and na¨ ıve CD4 T-cell counts. Although there is no statistically signiﬁcant evidence
of increased radiosensitivity in pregnant women, the increased slope of the linear trend line in the third trimester with respect to
stable chromosome aberrations is suggestive of an increased radiosensitivity.
1.Introduction
Several studies suggest that maternal radiosensitivity
increases during pregnancy, and that this eﬀect is mediated,
at least in part, by the elevated levels of steroid and/or
nonsteroid maternal hormones during pregnancy [1–
11]. The exact biochemical mechanism of this proposed
increased radiosensitivity is not well understood.
The Adult Health Study (AHS) population at the Radia-
tion Eﬀects Research Foundation (RERF) includes approxi-
mately 20,000 participants exposed to radiation during the
bombings of Hiroshima and Nagasaki, Japan in 1945 that
have been followed with biennial medical exams. In addition
to signiﬁcant eﬀects on cancer induction, there are a number
of long-term dose-response eﬀects detectable in A-bomb
survivors [12–17]. A subpopulation of women that were
pregnant at the time of the bombing and were exposed to
radiation provides a unique opportunity to test the hypoth-
esis that pregnant women show increased radiosensitivity.
Our premise was that this increased radiosensitivity during
pregnancy might be manifested by a greater dose-response
in long-term eﬀects in noncancer parameters. By comparing2 ISRN Obstetrics and Gynecology
Table 1: Distribution of pregnant and non-pregnant women in A-bomb survivors by cycle, city, and age at the bombs.
Cycle City Pregnant Age ATB
<20 <25 <30 <35 35+ Total
2 Hiro No 326 480 368 389 1264 2827
Yes 2 50 35 33 38 158
Naga No 167 186 127 85 211 776
Yes 4 10 17 5 9 45
22 Hiro No 217 319 145 99 45 825
Yes 3 32 18 7 1 61
Naga No 139 129 64 31 13 376
Yes 3 6 10 2 0 21
H: Hiroshima; N: Nagasaki.
the diﬀerence in dose-response in pregnant women with that
innonpregnantwomen,arelativemeasureofradiosensitivity
might be derived.
Our analysis focused on previously evaluated general
population dose-response lateeﬀects of radiation in A-bomb
s u r v i v o r so ns e r u mc h o l e s t e r o l( i n c r e a s e d )[ 16], white blood
cell (WBC) count (increased) [15], erythrocyte sedimenta-
t i o nr a t e( E S R )( i n c r e a s e d )[ 15], hemoglobin (HGB) level
(decreased) [17], stable chromosome aberration frequency
(increased) [12], glycophorin A (GPA) locus mutation rate
(increased) [18], and na¨ ıve CD4 T-cell counts (decreased)
[13].
We herein assess whether pregnancy at the time of the
bombings increased a woman’s radiosensitivity by compar-
ing the long-term eﬀects doseresponses in pregnant women
with that of non-pregnant women in the seven parameters
noted above.
2.MaterialsandMethods
2.1. Study Parameters. For purposes of analysis, the seven
parameters were broadly categorized as “indirect” or “direct”
eﬀects. The delineation was loosely based on whether or
not the endpoint measured depended on a more “indirect”
eﬀect of radiation, that is, requiring a cellular intermediary
or sustained cytokine interaction to manifest the end eﬀect
(cholesterol, WBC, ESR, HGB) or was the result of a
more “direct” eﬀect on a cell-type (stable chromosome
aberration, GPA locus mutation, and na¨ ıve CD4 T-cell
count). Those categories are not strictly deﬁned, but are
helpful in interpreting our results.
2.2.StudyPopulation. Subjectdatawasobtainedfrommoth-
ers of the 3,631 in utero study subjects that were originally
registered with the Atomic Bomb Casualty Commission
(ABCC)/RERF. A total of 2,452 women that were pregnant
at the time of the bombing (ATB) with a known dose
were included in the present study. Only 325 of these
women participated in some way in any of the AHS data
collection cycles. Attrition due to loss from followup and
deathfurtherdiminished theavailablestudypopulation. The
type of laboratory study data available increased in later data
collection cycles as more sophisticated analytical techniques
were developed.
Due to the disparity in data availability between the
“indirect” and “direct” eﬀects, we conducted two separate
cross-sectional analyses for this report. The ﬁrst analysis
was performed on data collected during AHS Cycle 2
(1960–1962), which had the maximum participation (250)
of women that were pregnant ATB. Laboratory data from
this cycle included the “indirect” eﬀect markers (serum
cholesterol, WBC, ESR, and HGB). The second analysis
involved data from women that participated in AHS Cycle
22 (2000–2002) when “direct” eﬀect test data (chromosome
aberration, GPA locus mutation, and na¨ ıve CD4 T-cell
count) became available. Due to attrition, data from a
maximum of only 85 pregnant women was available for
analysis in Cycle 22.
Separate and distinct populations for each of the cross-
sectional analyses were also drawn from the AHS database
for age and city-matched women that were not pregnant
ATB. Since the number of pregnant women was limited,
we expanded the age range for non-pregnant women to
include as large an amount of women as possible. Pregnant
women and non-pregnant women with unknown dose
were excluded from either analysis. The ﬁnal ratio of non-
pregnant to pregnant women was approximately 10:1 for
all study parameters. Demographic information for the
entire study cohort is presented in Table 1.D e m o g r a p h i c
information for the various subgroups is presented in Tables
1 and 2.
2.3. Measurement Methods
2.3.1. Total Cholesterol. Nonfasting serum cholesterol levels
were measure by the Kendall-Abell method [16].
2.3.2. WBC Count. Anticoagulated blood samples were
collected for measurement. WBC counts were obtained
manually by the Melangeur method [15].
2.3.3.ESR. Anti-coagulatedbloodsampleswerecollectedfor
measurement. ESR was measured by the Wintrobe method
[19] and corrected by a reading of the Wintrobe diagram
based on volume of packed red cells.ISRN Obstetrics and Gynecology 3
Table 2: Number of pregnant and non-pregnant women in A-bomb survivors by measurements, trimester and city.
(a)
Items Pregnant Not pregnant Two sided
Cholesterol
Number 58 819
Median age ATB (range) 27 (17, 43) 31 (17, 47) 0.090
First trimester (%) 22 (37.9)
Second trimester (%) 26 (44.8)
Third trimester (%) 10 (17.2)
Hiroshima (%) 36 (62.1) 577 (70.5) 0.231
Nagasaki (%) 22 (37.9) 242 (29.5)
Median dose (mGy) ((range) 172.0 (0, 2862) 115.5 (0, 3380) 0.170
WBC
Number 166 2368
Median age ATB (range) 28 (17, 44) 30 (17, 47) 0.019
First trimester (%) 58 (34.9)
Second trimester (%) 67 (40.4)
Third trimester (%) 41 (24.7)
Current Smoker (%) 24 (14.5) 403 (17.0) >0.5
Former (%) 3 (1.8) 56 (2.4)
Never (%) 139 (83.7) 1909 (80.6)
History of Inﬂammatory of disease (%) 40 (24.1) 643 (27.2) 0.443
Cancer (%) 1 (0.6) 12 (0.5) 0.693
Hiroshima (%) 129 (77.7) 1862 (78.6) 0.856
Nagasaki (%) 37 (22.3) 506 (21.4)
Median dose (mGy) (range) 97.2 (0, 2862) 134.6 (33.325) 0.223
ESR
Number 101 1466
Median age ATB, range 28 (19, 43) 32 (19, 47) 0.001
First trimester (%) 35 (34.7)
Second trimester (%) 41 (40.6)
Third trimester (%) 25 (24.8)
Current Smoker (%) 14 (13.9) 249 (17.0) 0.206
Former (%) 0 (0.0) 33 (2.3)
Never (%) 87 (86.1) 1184 (0.808)
History of Inﬂammatory of disease (%) 17 (0.168) 340 (23.2) 0.177
Cancer (%) 1 (1.0) 11 (0.8) 0.747
Hiroshima (%) 101 (1.0) 1466 (1.0) < 0.001
Nagasaki (%) 0 (0.0) 0 (0.0)
Median dose (mGy) (range) 76.3 (0, 2391) 157.4 (0, 3278) 0.033
(b)
HGB
Number 166 2368
Median age ATB, range 28 (17, 44) 30 (17, 47) 0.019
First trimester (%) 58 (34.9)
Second trimester (%) 67 (40.4)
Third trimester (%) 41 (24.7)
Current Smoker (%) 24 (14.5) 403 (17.0) 0.607
Former (%) 3 (1.8) 56 (2.4)
Never (%) 139 (83.7) 1909 (80.6)
History of Inﬂammatory of disease (%) 40 (24.1) 643 (27.2) 0.4434 ISRN Obstetrics and Gynecology
(b) Continued.
HGB
Cancer (%) 1 (0.6) 12 (0.5) 0.693
Hiroshima (%) 129 (77.7) 1862 (78.6) 0.856
Nagasaki (%) 37 (22.3) 506 (21.4)
Median dose (mGy) (range) 97.2 (0, 2862) 134.6 (0, 3325) 0.223
Stable chromosome
aberration frequency
Number 27 313
Median age ATB (range) 23 (20,34) 21 (17, 33) 0.003
First trimester (%) 10 (37.0)
Second trimester (%) 11 (40.7)
Third trimester (%) 6 (22.2)
Hiroshima (%) 18 (66.7) 213 (68.1) 0.947
Nagasaki (%) 9 (33.3) 100 (32.0)
Median Dose (mGy) (range) 121.7 (0, 1518) 287.6 (0, 3252) 0.328
GPA locus mutation
Number 26 327
Median age ATB (range) 24 (18, 32) 21 (17, 38) 0.005
First trimester (%) 7 (26.9)
Second trimester (%) 11 (42.3)
Third trimester (%) 8 (30.8)
Hiroshima (%) 23 (88.5) 214 (65.4) 0.029
Nagasaki (%) 3 (11.5) 113 (34.6)
Median Dose (mGy), range 4.3 (0, 1621.4) 80.1 (0, 2977) 0.322
Na¨ ıve CD4 T cell
count
Number 75 887
Median age ATB (range) 24 (17, 38) 21 (17, 38) <0.001
First trimester (%) 26 (34.7)
Second trimester (%) 33 (44.0)
Third trimester (%) 16 (21.3)
Hiroshima (%) 57 (76.0) 606 (68.3) 0.211
Nagasaki (%) 18 (24.0) 281 (31.7)
Median Dose (mGy), range 66.9 (0, 2027) 81.9 (0, 3311) 0.554
2.3.4. HGB Level. Hemoglobin level was measured by a
manual procedure with quality control procedures in place
to maintain reproducibility and consistency in laboratory
results [17].
2.3.5. Stable Chromosome Aberration Frequency. Chromo-
some spreads from peripheral blood lymphocytes were
prepared and Giemsa stained by conventional procedures
[20]. They were then classiﬁed into seven groups (A to
G). Metaphases were photographed for further karyotype
analysis if there was any deﬁnite or suspected change in
the number of chromosomes for any group. Chromosome
aberrations were classiﬁed into one of three types: reciprocal
translocations, pericentric inversions, or small deletions.
One hundred cells were scored for each blood sample. The
proportion of cells containing at least one aberration per 100
cells was recorded [12].
2.3.6. GPA Locus Mutation Rate. A single-beam cell sorter,
FACStar(BectonDickinsonImmunocytometrySystems,San
Jose, CA), was used to sort four types of variant erythrocytes
lacking the expression of one GPA allele that were distin-
guished from normal MN heterozygous cells. Those four
variants are MΦ,N Φ, MM, and NN. Mutant cells displaying
a hemizygous or homozygous phenotype were sorted onto
a glass slide, and counted under a ﬂuorescence microscope.
Typically, 106 erythrocytes were assayed per sample [14].
Among those four mutant types, the reproducibility of NN
cells was low, and MM mutant frequency was signiﬁcantly
aﬀected by overlapping MΦ mutants. Thus, in the report the
statistical analysis was undertaken for the mean of MΦ and
NΦ hemizygous mutations.
2.3.7. Na¨ ıve CD4 T-Cell Counts. Analytical ﬂow cytometry
was conducted in a FACScan machine (BD Biosciences,ISRN Obstetrics and Gynecology 5
San Jose, CA). Expression of CD45RA and CD4 molecules
was analyzed with FITC-labeled and PE-labeled antibodies,
respectively. In every measurement, approximately 20,000
cells were analyzed. The percentage of CD45RA−/CD4+
(na¨ ıve CD4 T-cells) in peripheral lymphocytes was deter-
mined [13].
2.4. Statistical Methods. Separate linear regression analyses
were performed based on the indirect and direct outcomes
selected. The outcomes for WBC, cholesterol and GPA were
logtransformedwithbase10toapproximatethetransformed
outcome as normal distribution.
For three of the indirect outcomes (HGB, WBC count,
and ESR), our model accounted for the inﬂuence of city
(Hiroshima or Nagasaki), smoking history (current, former,
never), age ATB (age at exposure), history of inﬂammatory
disease/inﬂammatory process (yes or no), cancer history
(yes or no), bone marrow radiation dose (DS02) in Gy
(continuous variable), and pregnancy (yes or no ATB). Thus,
the assumed simple model for the ith subject’s outcome can
be expressed as
E

yi

= β0 +β1Ci +β2Smi +β3Aai +β4IDi
+β5ACi +β6Di +β7Pi,
(1)
where β’s are regression coeﬃcients, E(yi) is the expectation
for the ith subject for the transformed or untransformed
outcome yi, Ci is the Nagasaki indicator, Smi is the smoking
indicator, Aai is the adjusted age equal to (age ATB-20)/10,
IDi and ACi are inﬂammatory disease and any cancer
indicators, respectively, Di is the radiation dose, and Pi is the
pregnancy indicator.
For total cholesterol, and the direct outcomes (na¨ ıve
CD4 T-cell count and GPA mutation rate), the independent
variables are city, adjusted age ATB, radiation dose and
pregnancy. Thus the assumed model for the ith subject for
these parameters can be expressed as
E

yi

= β0 +β1Ci +β2Aai +β3Di +β4Pi,( 2 )
where β’s are regression coeﬃcients, E(yi) is the expectation
for the ith subject for transformed or untransformed out-
come yi.
Because of the level of dispersion in the chromosome
aberration frequency results, a binomial model with linear
probability was used that had city, age ATB, smoking,
radiation dose, and pregnancy indicator as independent
variables and overdispersion was accounted for. The model
for chromosome aberration probability is
E

yi

= β0 +β1Ci +β2Aai +β3Smi +β4Di +β5Pi,( 3 )
where β’s are regression parameters, E(yi) is expectation of
chromosome aberration rate yi. The Wald test was used to
assess signiﬁcance of the eﬀect.
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Figure 1: Scatter plot of chromosome aberration frequency in
pregnant versus non-pregnant women with linear trend lines for
both groups. Open circles reﬂect control data from non-pregnant
women, while solid triangles reﬂect data from women pregnant
ATB.
3. Results
A tabular summary of our ﬁndings is presented in Tables 3.
3.1. Indirect Studies. No overall dose-response eﬀect was
found in serum cholesterol, WBC count, or ESR. Neither
was there a statistically signiﬁcant diﬀerence in the slopes
of the regression lines for pregnant versus non-pregnant
women. There was a suggestion of a statistically signiﬁcant
overall dose-response decrease (P = .088) in HGB level of
0.067gdl−1 Gy−1. However, the slope of the regression lines
for HGB level for pregnant versus non-pregnant women was
not statistically diﬀerent.
3.2. Direct Studies. Chromosome aberration frequency
demographic information is presented in Table 2(b). A sta-
tistically signiﬁcant overall dose-response increase in stable
chromosome aberration frequency of 0.899Gy−1 (P<. 001)
was found. The slope of the regression line for pregnant
women in Figure 1 indicated an overall increase in stable
chromosome aberration frequency (1.672Gy−1), although
this line was not statistically diﬀerent from the line for
non-pregnant women (0.878Gy−1), P = .378. Although
the numbers are very small, for those exposed in the
third trimester, the dose-response trend line in Figure 2 is
positive and steeper, suggesting a possibility of increased
radiosensitivity.
A statistically signiﬁcant overall dose response increase
in GPA locus mutation rate of 26.25Gy−1 (P<. 001) and
ad e c r e a s ei nn a ¨ ıve CD4 T-cell counts of 1.43Gy−1 (P =
.001) were found. The slope of the respective regression line
for pregnant women versus non-pregnant women was not
statistically diﬀerent.6 ISRN Obstetrics and Gynecology
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Figure 2:Scatterplotofchromosomeaberrationfrequencyinpreg-
nant versus non-pregnant women (ﬁrst two trimesters separated
from third trimesters) with linear trend lines for each group. Open
diamonds reﬂect control data from non-pregnant women, solid
triangles reﬂect women pregnant in the ﬁrst two trimesters ATB,
and solid squares reﬂect women pregnant in the third trimester
ATB.
4. Discussion
4.1. Review of Published Material. Several authors have
foundthatthenumberofchromosomeaberrationsin exvivo
irradiated peripheral blood lymphocytes (PBL) correlates
well with the degree of normal tissue late toxicity after radia-
tion therapy and may be useful as an indicator of a patient’s
inherent radiosensitivity [21–23]. Alternatively, interphase
cells can be examined for the presence of micronuclei that
may be used as an indicator of the degree of radiosensi-
tivity [24–27]. More recently, researchers have used gene
expression proﬁles of PBL to predict severe late toxicity with
radiation therapy [28]. These studies are in seeming contrast
to work by Sposto et al. who concluded that individual
diﬀerences in the dose response of chromosome aberrations
were not signiﬁcant enough to aﬀect the biodosimetry data
in a study of A-bomb survivors [29].
There are several preclinical studies that suggest that a
biochemical environment that emulates pregnancy may be
associated with an increased rate of radiosensitivity, albeit
early radiosensitivity as measured primarily by chromosome
aberrations in PBL shortly after irradiation. This literature is
summarized below.
Sharma and Das. demonstrated that there was a statis-
tically signiﬁcant increase in spontaneous sister chromatid
exchanges (SCE) in human PBL from females in the third
trimester of pregnancy compared to non-pregnant females
(10.7 versus 6.5, P<. 001) [10]. When estrogen, pro-
gesterone, and human chorionic gonadotropin were added
in physiologic concentrations consistent with pregnancy
in vitro to PBL from non-pregnant females, a statistically
signiﬁcant increase in SCE was noted after X-ray irradiation
to 2 to 3Gy (9.7 versus 5.6, P<. 001).
Roberts et al. demonstrated a statistically signiﬁcant
diﬀerence between females and male subjects in the total
number of chromosome aberrations (P = .006) and a trend
towards signiﬁcance in dicentric formation (P = .07) in PBL
after exposure of whole blood to high dose-rate radiation
(1.75Gy at 0.29Gy/min) [9]. The range of sensitivity in the
group of 50 healthy female volunteers was also signiﬁcantly
greater than in the male volunteers. Interestingly, there
was also a large variation in sensitivity over time among
samples from the same volunteer, implying a transitory
eﬀect. In evaluating this variation, it was noted that two
subjects had started taking hormonal therapy during the
course of sample collection. One volunteer, who was taking
conjugated estrogen alone, had no increase in chromosomal
aberrations over the course of the study. A second volunteer,
taking a progesterone/estrogen combination demonstrated
a 68% increase in her chromosome aberration count after
starting on hormonal therapy and this level continued after
termination of the hormone therapy.
Building on previous work showing similar results in a
pregnantmousemodel[5,6],Ricouletal.demonstratedthat
the rate of radiation-induced chromosomal breaks in ex-vivo
irradiated PBLs was, on average, higher in pregnant versus
non-pregnant humans [8]. Due to a much lower variation
in fetal chromosomal aberration with the term of pregnancy
in their previous work with mice, the authors suggested a
relationship with maternal hormones as these ﬂuctuations
are more pronounced on the maternal side during the course
of pregnancy. In a small longitudinal portion of this study,
radiation-induced chromosome aberrations in PBL were
noted to increase in the 30th week of gestation and drop
markedlyafterdeliveryofterminfantsandthatthisincreased
rate was more closely correlated with the serum level of
progesterone than estrogen.
Ricoul et al. subsequently demonstrated that the in
vitro addition of progesterone prior to irradiation resulted
in an increased frequency of chromosome rearrangements
and that this eﬀect was particularly eﬃcient at the G1/S
transition period. They suggest that the progesterone may
stimulate accelerated, and hence more error-prone, chromo-
some repair resulting in survival past S-phase, albeit with
illegitimate chromosome rearrangements [7].
Kanda and Hayata investigated the eﬀect of incubation
o fh u m a nP B Lw i t hv a r i o u sl e v e l so fe s t r a d i o ld u r i n ga n d
after irradiation to 3Gy at 1.4Gy/min [3]. They found that
at a level of 100ng/ml (consistent with the third trimester of
pregnancy) there was a statistically signiﬁcant 20% increase
in the radiation-induced formation of dicentrics and centric
rings (P<. 05), and that this level is in the range
associated with chromosome aberrations found in irradiated
lymphocytes from patients with hereditary retinoblastoma
[4]. They speculate based on other authors work with similar
ﬁndings in peripheral blood mononuclear cells [2], that it
is possible that the estradiol reduced the rate of apoptosis
resulting in a higher frequency of chromosomal aberrations
at subsequent metaphase.
Baeyens et al. found higher levels of micronuclei in
an in vitro assay of irradiated PBL from pregnant (third
trimester) versus non-pregnant humans [1]. They suggestISRN Obstetrics and Gynecology 7
t h a tw e a kv a r i a t i o n si nh o r m o n a ll e v e l sf a i lt oe n h a n c e
PBL radiosensitivity, but that important increases in serum
estradiol and progesterone, such as those found during
pregnancy, could increase PBL radiosensitivity.
Similar to the speculation by Kanda et al. noted above,
Vares et al. investigated the role of progesterone in modulat-
ing the eﬀects of radiation on several human breast cancer
cell lines [11]. They found that in progesterone receptor
positivecelllines,a10nMconcentrationofMPA(asynthetic
progestin) was suﬃcient to signiﬁcantly inhibit apoptosis
induced by in vitro irradiation of 4Gy. Progesterone treat-
ment was also shown to counterbalance radiation-induced
growth arrest and consequently increase the frequency
of chromosomal aberrations (measured via micronucleus
assay) in subsequent cell cultures.
In summary, several researchers have found that in vitro
irradiation of PBL from women that were pregnant, or PBL
irradiated in media that emulates concentrations of steroid
hormones consistent with pregnancy, tend to have a higher
level of chromosome aberrations suggestive of an increased
radiosensitivity.
In conducting this retrospective analysis, we expected
that the radiation dose-response in pregnant women, as
indicated by the slope of the individual regression line, for
our selected parameters would be steeper than that found in
the group of non-pregnant female A-bomb survivors.
It should be noted that there is a potential for signiﬁcant
selection bias at several levels in our analysis. First, as noted
in the methods section, only a small fraction of the women
that were pregnant at the time of bombings participated in
the AHS, and not all of these women had appropriate data
available for analysis. In addition, the selection of women
to participate in the original chromosome aberration and
GPA locus mutation rates published by previous authors
was predicated on a higher radiation exposure dose so
extrapolation of the dose rate eﬀect to the lower doses
experienced by the women in the present study may be
problematic.
4.2. Expected Results and Present Study Findings:Indirect
Studies. Wong et al. reported a signiﬁcant dose-dependent
increase in serum cholesterol level in a study involving more
than 9,800 A-bomb survivors with a mean dose of 1.09Sv
[16]. Neriishi et al. reported a statistically signiﬁcant dose-
response increase in WBC count (71.0 cellsmm−3 Gy−1,
P = .015) and an increase in ESR (1.58mmhr−1 Gy−1,
P = .0001) among more than 6,000 A-bomb survivors with
am e a nd o s eo f0 . 3 8 G y[ 15]. Wong et al. demonstrated a
statistically signiﬁcant reduction in serum hemoglobin level
for those exposed to 1Gy bone marrow dose of 0.10g/dl
(95% CI 0.04–0.16) at 40 years of age and 0.24g/dl (95%
CI 0.08–0.40) at 80 years of age in a study of more
than 7,000 survivors with a median dose of 0.43Gy [17].
While our ﬁndings were not inconsistent with those of
these previous studies, overall, there is no indication of
increased radiosensitivity in pregnant women with respect
to serum cholesterol, WBC count, serum ESR, or serum
hemoglobin.
These results are based on data collected during Cycle 2
of the AHS, 13–15 years after the bombings, and may not
reﬂect the true long-term incidence of late eﬀects in these
parameters. The published dose-response eﬀects to date have
involved the study of responses over much longer time
intervals. However, Cycle 2 contained the largest number
of women that were pregnant at the time of the bombings,
so using a later cycle for analysis would further limit the
statistical power of any ﬁndings.
4.3. Expected Results and Present Study Findings:Direct Stud-
ies. In a study involving over 3,000 A-bomb survivors,
Kodama et al. demonstrated the existence of stable chro-
mosome aberrations (at least one translocation or inversion
per 100 lymphocytes per person) occurred at a rate related
to the radiation exposure dose with an alpha/beta ratio of
approximately 1.7Sv (95% CI 0.9–4) [12].
For our study, an overall positive dose-response chro-
mosome aberration eﬀect was found that is in accordance
with that found by Kodama et al. Although their results are
not statistically diﬀerent, both pregnant and non-pregnant
women show a signiﬁcant positive dose-response eﬀect.
Graphically in Figure 1, this appears to be more substantial
in pregnant women, but due to overall low data availability,
statistical signiﬁcance was not attained. As can be seen
in Table 2(b), the pregnant women cohort represents a
statistically older population that was subject to statistically
suggestive lower median radiation dose. Overall, there is
no clear indication of increased radiosensitivity in pregnant
women with respect to chromosome aberration frequency.
As shown in Figure 2, the dose-response trend line is
suggestively steeper for the small number of women in the
third trimester. However, power calculations demonstrate
that data from an additional 684 pregnant women in the
third trimester would be required to show a statistically
signiﬁcantdiﬀerencefromnon-pregnantwomen.Additional
chromosome aberration data is being collected using more
modern techniques, but there were simply not enough preg-
nant women in the third trimester to allow for statistically
signiﬁcant separation of the dose-response trend lines.
Regarding GPA locus mutation, Kyoizumi et al. studied
the mutation rate among more than 1,000 A-bomb survivors
with a mean age of 64 and found a doubling dose of
1.2Sv (95% CI 0.95–1.56) with a minimum dose to detect
increased mutation of 0.24Sv (95% CI 0.041–0.51) [14].
It was postulated that the mutability of the GPA locus is
indicative of the nonspeciﬁc mutability of all somatic cell
lines, including genetic loci of cancer-associated genes [18].
An overall positive dose-response eﬀect with respect to
GPA locus mutation was found that is in accordance with
that found by Kodama et al.; the overall dose-response rate
was 26 mutations Gy−1. However, there was no signiﬁcant
diﬀerence in the regression lines for pregnant versus non-
pregnant women.
Regarding na¨ ıve CD4 T-cell counts and building on
previous work that demonstrated a decreased count in 159
A-bomb survivors exposed to more than 1.5Gy of radiation
[30],Kusunokietal.studiedlymphocytesfrom553survivors8 ISRN Obstetrics and Gynecology
and demonstrated a statistically signiﬁcant dose-dependent
decrease in percentage of circulating na¨ ıve CD4 and CD8 T-
cells. They also studied lymphocytes from 723 atomic bomb
survivors and demonstrated a statistically signiﬁcant dose-
dependent decrease in the percentage of circulating na¨ ıve
CD4 T-cells [13].
Anoverallnegativedose-responseeﬀectwasfoundthatis
in accordance with that found by Kusonoki et al.; the overall
dose-response rate was a decrease of 1.42Gy−1.H o w e v e r ,
there was no signiﬁcant diﬀerence in the regression lines for
pregnant versus non-pregnant women.
Numeric result data for all parameters is presented in
Table 3.
4.4. Rationale for Continued Study. In general, diagnos-
tic imaging and radiation therapy are proscribed during
pregnancy, more for the well-documented potential for
harm to the developing fetus than for the protection of
the expectant mother. However, there can be inadvertent
radiation exposure for diagnostic imaging during an occult
pregnancy. Also, diagnostic images are occasionally obtained
in women during the third trimester since by that time the
fetus is generally thought to be less susceptible to catas-
trophic radiation damage (intrauterine death, microcephaly,
mental retardation) and the low-rate of long-term cancer
induction risk to the fetus may be outweighed by the
need for diagnostic imaging or treatment in the mother
[31]. Unfortunately, in previous studies with peripheral
blood lymphocytes (PBL), the third trimester appears to be
potentially the most at-risk phase for the pregnant women
in terms of the potential for increased radiosensitivity [1–
11]. For informed consent purposes, physicians must fully
relate the potential for increased risk due to the diagnostic or
therapeutic maneuver both to the developing fetus as well as
the expectant mother.
What we learn from studies on radiosensitivity and
hormones may have implications for understanding the role
of the hormonal milieu on radiation therapy-induced tumor
and normal tissue eﬀects. Radiation therapy is commonly
used in women who may beneﬁt from antiestrogens and
aromatase inhibitors as part of their treatment for breast
cancer. It is important to understand if these agents, which
aﬀect the production or interaction of estrogen with its
cellular receptor, markedly alter the sensitivity of the tumor
and/or normal tissues to the eﬀects of radiation therapy.
Small studies have demonstrated in vitro cell-cycle redistri-
bution eﬀects and alterations to tumor cell survival curves
with concurrent anti-estrogen exposure [32, 33].
Clinically, several retrospective studies have demon-
strated no increased acute or late adverse eﬀects or impact
on local control with concurrent versus sequential radiation
therapy and hormonal therapy for early stage breast cancer
[34–36], but several other studies demonstrate increased
incidence of early and late lung injury [37]a sw e l la s
increased breast ﬁbrosis [38]. An in vivo study with a human
breast cancer cell line demonstrated a radiosensitizing eﬀect
of a therapeutic level of letrozole with radiation doses
ranging from 0 to 4Gy [39].
To date, there are no published in vivo, prospective,
randomized trials to evaluate the concurrent use of anti-
estrogens or aromatase inhibitors and radiation therapy.
It is also possible that other metabolic conditions other
than the level of circulating hormones may also aﬀect the
relative radiosensitivity of women who are pregnant at the
time of exposure. For example, as pregnancy is a hyperme-
tabolic state and is associated with increased oxidative stress
[40, 41], it is possible that this higher metabolic state results
in the circulation of an increased level of free radicals that act
to exacerbate the oxidative damage of radiation exposure.
5. Conclusions
There is no statistically signiﬁcant evidence of changes in
variousbiomarkerstosuggestanincreasedradiosensitivityin
women that were pregnant ATB in Hiroshima and Nagasaki
ascomparedtonon-pregnantcontrolsubjects.Wecompared
the late eﬀects of changes in serum cholesterol, WBC
count, ESR, HGB, stable chromosome aberration, GPA locus
mutations, or na¨ ıve CD4 T-cell counts.
Theincreasedslopeofthetrendlineinthethirdtrimester
with respect to stable chromosome aberrations is suggestive
of an increased radiosensitivity, but there are not enough
pregnant women in the third trimester in the AHS database
to demonstrate statistical signiﬁcance.
A separate protocol is underway to determine if cancer
incidence(particularlybreast,skinandthyroid),cancermor-
tality, or all-cause mortality is increased in women that were
pregnant ATB. This study will have the advantage of using
the much larger Life Span Study (LSS) database, containing
information on approximately 120,000 survivors, and may
have suﬃcient power to identify even small diﬀerences.
T h er e l a t i v ee ﬃcacy and toxicity associated with the
concurrent use of anti-estrogens and aromatase inhibitors
should be evaluated in a randomized trial setting with
long-term followup to determine if these agents change the
therapeutic index by altering the production and/or cellular
interaction of estrogen.
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Table 3: Summary of expected and actual ﬁndings in pregnant A-bomb survivors—direct eﬀects.
(a)
Parameter(Reference interval) Expected change with pregnancy Regression Coeﬃcients Standard Error P-value
Log-Cholesterol (143–220mg/dl)∗ (Log-mg/dl/Gy)
Overall   +0.006
 
0.005 .259
Pregnant −0.015 0.020 .435
Not pregnant +0.007 0.005 .166
Diﬀerence .264
Log-WBC count (33–91103cells/cm3)∗∗ (Log-cells/cm3/Gy)
Overall   −0.001 0.004 .726
Pregnant −0.009 0.019 .633
Not pregnant +0.002 0.004 .646
Diﬀerence .573
ESR (0–40mm/hr)∗∗ (mm/hr/Gy)
Overall   +0.485
 
0.427 .255
Pregnant −2.884 2.189 .188
Not pregnant +0.617 0.435 .156
Diﬀerence .117
HGB (11–15g/dl)∗∗ (g/dl/Gy)
Overall
 
−0.067
 
0.039 .088
Pregnant +0.139 0.187 .456
Not pregnant −0.077 0.040 .057
Diﬀerence .258
∗Adjusted for age and city.
∗∗Adjusted for age, city, smoking, inﬂammatory disease, and any cancer.
(b)
Parameter Expected change with pregnancy Regression Coeﬃcients Standard Error P-value
Chromosome aberration∗∗ (freq/cell/Gy)
Overall   +0.0708
 
0.00439 <.001
Pregnant +0.0864 0.0194 <.001
Not pregnant +0.0699 0.00450 <.001
Diﬀerence .403
Log-GPA locus mutation∗ (Log-mut/Gy)
Overall   +0.281
 
0.029 <.001
Pregnant +0.414 0.141 .004
Not pregnant +0.275 0.029 <.001
Diﬀerence .337
Na¨ ıve CD-4 T-cell count∗ (cells/Gy)
Overall
 
−1.425
 
0.419 .001
Pregnant −1.551 1.939 .424
Not pregnant −1.419 0.429 .001
Diﬀerence .947
∗Adjusted for age and city.
∗∗Adjusted for age, city, and smoking.10 ISRN Obstetrics and Gynecology
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